{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-044406","form_type":"8-K","ticker":"VRDN","cik":"0001590750","company_name":"Viridian Therapeutics, Inc.\\DE","filed_at":"2025-03-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.099640+00:00","generated_at":"2026-05-25T14:01:06.786663+00:00","sec_items":["1.01","1.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Viridian Therapeutics enters $300M ATM equity offering with Jefferies; terminates prior $175M ATM","bullets":["New Open Market Sale Agreement with Jefferies LLC allows sale of up to $300M in common stock.","Proceeds to fund clinical development of veligrotug and other candidates, plus commercialization preparation.","Prior $175M ATM agreement terminated; $115.2M of shares sold under it.","Jefferies will receive up to 3% commission on gross proceeds; no obligation to sell shares.","Company may suspend or terminate sales at any time."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-044406","json":"https://secwatch.observer/filing/0001193125-25-044406.json","markdown":"https://secwatch.observer/filing/0001193125-25-044406.md","text":"https://secwatch.observer/filing/0001193125-25-044406.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1590750/000119312525044406/0001193125-25-044406-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1590750/000119312525044406/d909216d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T14:01:06.786663+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}